Larotrectinib monotherapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Trial Timeline
Feb 14, 2024 → Oct 1, 2027
NCT ID
NCT05783323About Larotrectinib monotherapy
Larotrectinib monotherapy is a phase 2 stage product being developed by Bayer for Differentiated Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05783323. Target conditions include Differentiated Thyroid Cancer, Pediatric Cancer, Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05783323 | Phase 2 | Recruiting |
Competing Products
20 competing products in Differentiated Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| Selpercatinib Monotherapy | Eli Lilly | Phase 2 | 52 |
| Selumetinib + Placebo + Radioactive Iodine Therapy | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 52 |
| Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo | Novartis | Phase 3 | 77 |
| PDR001 | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| sunitinib | Pfizer | Approved | 84 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 76 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 76 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |